Background. We sought to compare the immunoreactive potential of human cord
blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (pe
ripheral blood stem cells; PBSC) from cancer patients.
Methods. Forty mice were randomized to receive a range of doses of T cell-r
eplete cell preparations from one of the above three cell. sources. Twenty-
eight control mice underwent transplantation with T cell-depleted cells. Mi
ce were observed for 60 days for the development of fatal xenogeneic graft-
versus-host disease-like syndrome (GVHDLS).
Results. For the mice that had received T cell-replete grafts of CB or BM o
r PBSC, the duration of GVHDLS-free survival of the chimeras was inversely
proportional to the number of T cells transplanted. After adjustment for th
e number of T cells transplanted, the relative hazard of developing fatal G
VHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared wi
th CB. Flow cytometric and histologic analyses of selected chimeras that di
ed of GVHDLS showed extensive proliferation of human T cells in multiple or
gans. In contrast, mice that survived to day 60 were engrafted with human m
yeloid and B lymphoid cells.
Conclusions. The immunoreactive potential, as measured by this in vivo assa
y, differed among clinical grafts: BM > PBSC > CB.